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Medicines and medical devices containing animal-derived ingredients are frequently used on patients without their 
informed consent, despite a significant proportion of patients wanting to know if an animal-derived product is going 
to be used in their care. Here, I outline three arguments for why this practice is wrong. Firstly, I argue that using 
animal-derived medical products on patients without their informed consent undermines respect for their autonomy. 
Secondly, it risks causing non-trivial psychological harm. Thirdly, it is morally inconsistent to respect patients' 
dietary preferences and then use animal-derived medicines or medical devices on them without their informed 
consent. I then address several anticipated objections and conclude that the continued failure to address this issue is 





Western countries have become increasingly diverse and multicultural, and the population holds 
a variety of religious and secular beliefs about the use of animals in food, clothing, research, or 
medical products. The number of individuals with such dietary preferences has increased steeply 
in recent years as have those with concerns about the use of animal-derived products in 
healthcare. By an animal-derived product in healthcare I mean any medicine or medical device—
implant, suture, dressing, tissue graft, vaccine—that contains an animal-derived ingredient. The 
scale of this problem is significant—of the 100 most prescribed drugs in primary care in the UK, 
74 contained an animal-derived product [1].  
 
These concerns are not new—more than 1700 years ago the Hellenistic philosopher Plotinus, 
who was a vegetarian, refused medicines with animal substances [2]. For Muslims, products 
containing animal-derived products are unlikely to be halal—compatible with Islamic dietary 
laws. In 2017, the Muslim population in the United States (US) was estimated at 3.45 million and 
is expected to represent 2% of the population by 2050 [3]; in the United Kingdom (UK) in 2018 
the Muslim population numbered over 3.3 million [4]. Hindus are also another significant group 
that have dietary preferences, and number over 1 million in the UK [4]. Furthermore, research 
commissioned by The Vegan Society found that over 500,000 of the over-15 population in the 
UK follow a vegan diet which amounts to more than a 300% increase since 2006—a significant 
proportion of who avoid non-dietary animal products [5].1 Similar trends have occurred in the 
US where it is estimated that there are now more than 9 million vegans, accounting for 3% of 
the population [6].  
 
It is routine in liberal societies for hospital inpatients to be asked about their dietary preferences 
to avoid providing food that conflicts with their beliefs. There is no expectation that patients 
must self-declare this information. Patients expect to have their dietary preferences respected, 
and for a patient to be given something that contravenes their wishes would be understood to 
have caused harm. For instance, there are examples of vegetarians accidentally given meat who 
have described their experiences in traumatising terms—feeling ‘defiled’ [7]. A concern is that 
many patient’s dietary preferences may also be reflected in their beliefs about the use of animal-
derived products used in other contexts—such as healthcare—and that this is a problem that is 
not currently getting the attention it deserves.  
 
If a problem does exist then it is on a remarkable scale, with potentially hundreds of thousands 
of patients each year in the UK receiving animal-derived products to which they never 
consented. There are a growing number of ethicists and clinicians—such as surgeons and 
pharmacists—who argue that the principle of informed consent entails that the use of animal-
derived products should be disclosed to patients [8,9,10,11]. However, there are several 
challenges to satisfying this commitment. Firstly, many clinicians may be unaware of all the 
medicines and medical devices that contain an animal-derived product and this information is 
not always easily accessible and sometimes unclear or incorrect [1]. Secondly, it would also 
require clinicians to know whether there was a non-animal derived alternative available. In many 
jurisdictions, pharmaceutical companies are only required to record the active ingredients and 
not the excipients, despite typically making up 90% of the formulation of a drug—this is 
something that would need to change [11]. Only then can there be greater transparency on the 
labelling of medicines and medical devices. These problems are not easily navigated and would 
 
1 In further support of this trend, in 2020 every UK supermarket has its own vegan range, and most top restaurants 
have a vegan or plant-based option. 
require significant local and national change. 
 
It is not far-fetched to believe that some people would feel upset to discover that animal-derived 
products were used in their care—or their child’s without their consent. I argue that there are 
good ethical reasons for clinicians to begin routinely disclosing to patients where a known 
animal-derived product is intended to be used, administered or prescribed. I conclude by 
showing that respect for autonomy and informed consent are being applied inconsistently and 
that the disclosure of animal-derived products should become routine practice. 
 
Do patients want to know? 
 
Dietary preferences will not necessarily translate into concerns about the use of animal-derived 
products in healthcare. Nevertheless, research exploring this question has consistently shown 
that many patients would object to the use of certain animal-derived products in their care, whilst 
others only want the opportunity to give their informed consent.  
 
A study conducted in the US surveyed the views of 100 patients on animal-derived products in 
medication, and 63% wanted to be informed about their use by their physician [12]. The 
importance of disclosure is evidenced in several case studies, where the failure to disclose the 
presence of excipient animal-derived products in medication led to non-adherence, relapse, and 
hospitalisation [13]. A survey of 13 representative religious leaders in the UK showed that 77% 
believed that consent should be gained from patients for skin substitutes and dressings that 
contain a biological product [14]. This is congruent with the views expressed by international 
religious leaders [15].  
 
A survey of 534 patients in three West Midlands otolaryngology outpatient departments found 
that 44% wanted to be informed about the use of biological products—primarily animal-derived 
products—if they underwent surgery, and 17% objected to the use of any biological products 
during surgery [16]. Even in an emergency 7% of patients would not accept a biological product, 
further highlighting the significance this has for many patients. Most objections against the use 
of biological products were predicated on religious grounds, however, 11% of atheists also 
objected. The latter observation is unsurprising as there exists a strong correlation between 
atheism and veganism—in one survey of American vegans more than 50% self-identified as 
atheists [17]. A study of patients at a US Dermatology centre showed that 74% of patients 
wanted to know if an animal-derived product would be used on their skin. Furthermore, for 40% 
of patients the presence of an animal-derived product in their sutures would affect their 
treatment preferences [18].  
 
The evidence strongly supports the contention that patients' ethical or religious dietary concerns 
can extend to the use of animal-derived-products in healthcare. The studies that have been 
conducted so far consistently show that a significant proportion of patients want to be informed 
about the use of animal-derived products in their care.  
 
Disrespect for Autonomy 
 
Since the late 1970s respect for patient autonomy has been one of the fundamental ethical 
principles that undergirds the patient-clinician relationship, ensuring that decisions about a 
patient's care are made collaboratively rather than paternalistically2. A valid consent process 
requires sufficient and understandable information to be conveyed that is relevant to his or her 
decision [19]. Prior to the Montgomery v Lanarkshire Health Board [2015] ruling in the UK 
clinicians were free to disclose information to patients that they believed was relevant based on 
their clinical expertise and judgement [20]. However, since the Montgomery ruling, clinicians are 
expected to tell patients what they want to know and not only what they think they should be 
told—it established a duty of care to make patients aware of any material risks. A material risk 
describes a risk that a patient would ascribe significance to: “a reasonable person in the patient’s 
position would be likely to attach significance to the risk, or the doctor is or should reasonably 
be aware that the particular patient would be likely to attach significance to it.” [21]. Despite the 
immediate context referring to the risks associated with a medical procedure, it is not 
unreasonable to conclude that a patient may ascribe significance to unknowingly having an 
animal-derived product used in their medical treatment.3 
 
Wanting to be informed about the use of animal-derived products may seem like an 
unconventional belief, however, Tom Beauchamp and James Childress argue—‘to respect 
autonomous agents is to acknowledge their right to hold views, make choices, and to take actions 
based on their values and beliefs’ [22]. Arguably, by not considering the significance that many 
patients would attach to this belief, a substantial number of patients are routinely having their 
 
2 Though it is worth noting that respect for autonomy may not be necessary to guard against paternalism, see Saad 
[23].  
3 Or in a drug they are prescribed.  
autonomy disrespected [9]. Moreover, not only does the Montgomery ruling provide prima facie 
support for the disclosure of animal-derived products to patients, but so does the ethical 
guidance from the General Medical Council (GMC). The GMC recommends that patients' 
cultural, religious, and other beliefs and values are considered when treating them [24]. The 
decision to avoid animal-derived products can be an expression of religious or secular values that 
if violated can lead to patient harm, and by not considering the impact of this it is not clear that 
this guidance is being adhered to by clinicians.  
 
Many patients want to be given the opportunity to give their informed consent and failure to ask 
a clinician should not be considered tacit consent to their use. There may well be procedural 
challenges in identifying patients who would attach significance to the use of animal-derived 
products. Here, I only argue what ethical consistency ought to demand and not how it should be 
actioned in practice, whilst acknowledging the significant challenges that would be involved in 
achieving this. There are also further complicating factors, for instance, what about parents of 
children who do not want the most efficacious treatment to be used because it contains an 
animal-derived product?4 In one case, a 14-year-old child had their successful skin graft removed 
after their Muslim parents later discovered it contained porcine-derived products. This 
subsequently led to a significant loss of function in the child’s arm [25,26].5 Importantly, if the 
use of an animal-derived product had been explained to the parents during the consent process, 
an alternative treatment could have been explored and the negative outcome prevented. 
 
Non-trivial Psychological Harm 
 
The history of medicine is replete with examples of psychological harm caused to patients when 
certain information was withheld from them—importantly this information would have been in 
their interest to know. For instance, the practice of performing educational pelvic exams under 
general anaesthesia without informed consent [27]. Harm is commonly understood as the 
wrongful setback to a person’s interests [28]. In medical ethics, the principle of nonmaleficence 
states that there is an obligation not to cause unnecessary harm to others [22]. There are many 
ways in which clinicians can harm their patients, with negligence in performing a procedure 
being the most obvious example. However, harm can also be inflicted by failing to disclose 
 
4 Similar issues have arisen in England where some Muslim parents have refused to let their children receive the 
nasal flu vaccine Fluenz because it contains porcine gelatine [29]. 
5 For a comprehensive exploration of the problems associated with moral pluralism in secular clinical ethics, see 
Brummett [30] and Hassanein an Anderson [31].  
information to patients that was in their interest to know, resulting in a course of action that the 
patient may not have agreed to had the information been disclosed. The most common example 
of this is the failure to disclose the potential risks and complications of a procedure. There are, 
however, less obvious ways of harming patients by failure to disclose information. For example, 
Jehovah’s Witness adherents have a strong religious objection to receiving allogeneic blood 
transfusions, and if a transfusion is administered without their consent, psychological harm could 
result when they become aware of it. 
 
Another example of psychological harm potentially being caused to patients is when clinicians 
use animal-derived products on them without their informed consent. Despite some discussion 
in the literature over the last decade [7,8,9,10,11,15,18,31,32,33,34], the use of animal-derived 
products on patients without their consent is a practice that largely continues unencumbered. 





 A Muslim patient is admitted for an elective hernia repair and because of some pre-existing health conditions is 
admitted as an inpatient the evening prior to his surgery. Shortly after arrival on the ward he is asked if he has 
any dietary preferences and he notes that as a Muslim he will eat only food that is Halal and will not eat pork. 
The following morning the surgeon arrives to consent the patient and they agree that a mesh will be used for the 
hernia repair. The surgery is completed without incident and the patient is discharged later that evening. After the 
surgery the patient discovers that a biologic hernia mesh derived from porcine dermis was used and feels angry and 
defiled. 
 
In this scenario the patient's wishes not to eat pork are treated with respect whilst these 
preferences are disregarded with respect to his surgery. It remains unclear why one preference 
should be routinely respected and the other should not; the psychological harm caused by failing 
to disclose the use of animal-derived products may be similar or equal to not respecting a 
patient's dietary preferences. Discussing the presence of an animal-derived product in the 
consent process would have provided an opportunity to explore alternative hernia meshes and 
avoid the psychological harm caused. Perhaps an alternative hernia mesh would be less 
efficacious but that remains the patients choice and clinicians are obligated to discuss reasonable 




A vegan patient receives the first of two COVID-19 vaccine doses and it is administered without any issues. 
However, a week later she discovers that the vaccine was tested on rhesus macaques and mice. This was never 
disclosed to her or described in the patient leaflet [35]. She is distressed to discover this and subsequently decides 
that she will not accept the second dose of the vaccine. 
 
Compared with scenario 2 there is nothing in the vaccine itself that is animal-derived6. However, 
it is not currently legal to complete human vaccine trials without first completing testing on 
animals and so animals would have been harmed in this process. On first appearances this may 
seem outlandish, however, some vegans have argued that they will not accept any COVID-19 
vaccine that ‘exploits’ animals, irrespective of how serious the pandemic is [36].7 Importantly, 
ethical vegans  are now recognised as having philosophical beliefs that are a protected 
characteristic under the Equality Act 2010 [37]. Compared to the first scenario there is no 
alternative available and the only option for someone with this concern is to either accept that 
using any medication requires a degree of compromise, or reject the vaccine outright.8 Despite 
there being no acceptable alternative vaccine available this does not remove the obligation to 
disclose information that would have significance to a particular patient. If a Jehovah’s Witness 
patient requires a life-saving allogeneic blood transfusion there may be no alternative9 and yet the 
principles of nonmaleficence and respect for autonomy require their informed consent. The fact 
that alternatives do not exist does not remove the requirement for informed consent. 
 
It is not prima facie unreasonable for individuals to want to know about the origins—testing, 
development, and ingredients—of a vaccine. The origins of a vaccine or any other medicines 
may have moral significance to many people. For instance, human embryonic kidney cells were 
used during testing of some COVID-19 vaccines [38], and yet despite the moral significance of 
this practice it is not routinely disclosed and information that is easily accessible. There are 
obvious concerns with doing so—some individuals may decide to decline vaccination leading to 
 
6 Several vaccines routinely used in the UK include animal-derived products, for instance, Fluenz Tetra®, MMR 
VaxPro®, and Zostavax® all contain porcine. 
7 The Vegan Society released a statement that highlights how stressful and upsetting it can be to compromise their 
beliefs and that each individual should make an informed decision [39] 
8 The latter could be understood as a way to strongly encourage the scientific community to explore and develop 
effective alternative non-animal research methods. 
9 Apart from the use of intraoperative cell salvage. 
a decline in vaccination rates. However, rather than ignoring these concerns and allowing 
misinformation and conspiracy theories to flourish, [40] a more transparent approach rooted in 
accurate disclosure may help to alleviate vaccine hesitancy rather than worsen it.10 
 
Ethical Blind Spot 
 
Why do hospitals respect ethical and/or religious beliefs when it comes to dietary preferences, 
but then use medicines and medical devices that seemingly contravene those same beliefs 
without routinely disclosing it to patients? There is not any obvious ethical principle that applies 
in one scenario but not in the other. Perhaps this moral inconsistency is an example of 
benevolent paternalism—because routine disclosure of the presence of animal-derived products 
risks causing patient harm. There are two obvious risks to the patient: firstly, there may be no 
alternative treatment; and secondly, the alternative could have a reduced efficacy. In the case of 
respecting patient’s (or patients’) dietary preferences, alternatives can always be provided, but, in 
the case of medicines and medical devices this is not always possible. If no alternative is available 
then disclosure risks instigating a cascade of events that could lead a patient to reject a treatment 
that would otherwise be in their best interest to receive. However, we cannot pick and choose 
how or when we respect autonomy, even if doing so risks leading to an undesirable outcome. 
Respecting a patient’s autonomy means having to respect their right to make decisions on the 
basis of their own ethical values or religious beliefs, even if we might disagree with the likely 
outcome of that decision. 
 
An alternative explanation for this inconsistency is that it is a kind of ethical blind spot. An 
ethical blind spot is a lack of awareness that obscures the ability to recognise certain morally 
relevant features of a situation [41]. In this case, the relevant ethical principles are being rightly 
applied in one context—dietary preferences—but there is a lack of awareness of their application 
in the context of medicines and medical devices. On the one hand, respect for autonomy is 
considered one of the core ethical principles of medical ethics and yet it is frequently 
inconsistently applied with respect to the use of animal-derived products. This is an ethical 
failure, but I do not intend to impart moral guilt; instead, I only want to expose the ethical blind 
spot so that important ethical principles can be applied fairly to all patients.  
 
 
10 The failure of public transparency and individual disclosure is likely to have helped to facilitate an increase in anti-
vaccine sentiment and vaccine hesitancy—a particular concern during the COVID-19 pandemic. 
Potential objections and responses 
 
Here, I address several possible objections against disclosing the use of animal-derived products 
to patients. The primary difficulties with my proposal are related to the consequences of 
disclosure and whether patients expectations can be accomodated. 
 
Economic cost objection 
 
Informing patients that products used in their care may include animal-derived products might 
incur a significant economic cost at a time when health services are already under significant 
financial pressures. 
 
In response, it is possible that the disclosure of animal-derived products could result in increased 
economic costs. Additional costs would most likely result from the use of more expensive 
alternatives. In some cases the additional cost of some alternatives could financially impact 
service provision. However, it is not obvious that the obligation to disclose entails an obligation 
to provide costly alternatives or for patients to demand them. It seems reasonable to absorb 
some additional costs to avoid causing harm to patients but this will ultimately have a limit to 
ensure the fair distribution of health-resources. Therefore, it may not be possible to 
accommodate all of the available alternatives due to the limited resources available. This means 
that in some cases patients may be left with a troubling decision—compromise their ethical 
and/or religious beliefs, or forgo the intended benefits of the treatment or medication. It will be 
the responsibility of health services to decide how they balance the obligation to respect patient 
autonomy with any additional costs this may incur.  
 
Patient refusal objection 
 
If the presence of an animal-derived product in a treatment is disclosed to a patient, they might 
refuse the treatment, therefore denying the patient of the intended health benefits. 
 
This objection is one of the primary troubling implications of what I am proposing. There is 
research showing that some individuals would refuse prescribed oral medication if it contained 
animal-derived ingredients, even if there was no alternative treatment available [42]. Yet, 
provided the patient is capable of making an informed decision, it is their prerogative to refuse 
treatment—this is the nature of informed consent. Furthermore, there is evidence that most 
patients who object to the routine use of animal-derived products in their care will accept such 
treatment in an emergency, or when no alternative exists [15,32] 11. Nevertheless, some patients 
may decide that they do not want animal-derived products used in their care and even if a 
suitable alternative cannot be found the patient's autonomy must still be respected.  
 
Failure to disclose the presence of animal-derived products also risks facilitating medication non-
adherence which can result in several negative outcomes12 [13]. First, medication non-adherence 
of antibiotics or anticoagulants can in some cases cause relapse, worsening of symptoms and an 
increased mortality risk [43]. Second, it may compound existing scepticism of the medical 
community, leading to increased disengagement with healthcare services. Furthermore, when 
explaining any risks a treatment poses during the standard informed consent process there is 
already a possibility that doing so could result in a patient declining the proposed treatment and 
its intended benefits.  
 
Time constraints objection 
 
 Informing patients that products used in their care may include animal-derived ingredients will 
require additional time demands on clinicians who are already under significant time restraints. 
 
It seems self-evident that disclosing the use of animal-derived products will increase demands on 
a clinician’s time. In the majority of cases patients will likely not have any objections, but in a 
minority of cases this could amount to a significant demand on their time. Arguably, as 
disclosure is normalised it is likely that those time demands are likely to decrease as patients 
themselves become more informed about the relevant issues. Ultimately, if the use of animal-
derived products ought to be disclosed then the additional demands on time are not sufficient to 
outweigh doing so. This is because many patients may not know that medicines and medical 
devices can contain animal-derived products and because they could attach significance to it, 
disclosure would allow them to ask the types of questions they would have done if they had 
known [45]. However, like any other limited resource, clinician time must be fairly distributed 
and balanced against patient need to ensure maximising benefits to all patients. This highlights 
 
11 An example of this is a precedent in Islamic teaching that permits the use of otherwise prohibited ingredients 
when there is no alternative, see Ali and Maravia [44]. 
12 Patients in these case studies were subsequently prescribed medication that did not contain an animal-derived 
product.  
the challenges involved with balancing respect for autonomy with nonmaleficence and there are 




A growing number of patients want to know whether animal-derived products are used in their 
care.  Patients’ ethical or religious dietary preferences in many cases do extend to the use of 
animal-derived products in healthcare and the failure to address this issue is an ethical blind spot. 
Currently, there remains a lack of consistency regarding whether or not patients are informed 
about the use of animal-derived products despite the risk of psychological harm, failure to 
respect autonomy, and the implications of the Montgomery ruling. These are significant 
concerns that warrant a change in practice to routine disclosure. However, doing so risks 
opening a Pandora’s box of challenges that are neither insubstantial or easily resolved. Once 
there is agreement that this problem needs addressing, it will take a collaborative approach to 
navigate the challenges to satisfying this commitment. Despite some of the troubling 
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